Ajanta Pharma Limited (AJANTPHARM.BO)
INR 2491.9
(4.95%)
INR 2491.9
(4.95%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 19.67 Billion INR | 56.63% |
| 2022 | 6.61 Billion INR | -18.08% |
| 2021 | 8.07 Billion INR | -9.26% |
| 2020 | 8.9 Billion INR | 51.48% |
| 2019 | 5.87 Billion INR | 18.83% |
| 2018 | 4.94 Billion INR | -18.54% |
| 2017 | 6.07 Billion INR | -9.02% |
| 2016 | 6.67 Billion INR | 23.0% |
| 2015 | 5.42 Billion INR | 19.61% |
| 2014 | 4.53 Billion INR | 39.64% |
| 2013 | 3.24 Billion INR | 70.7% |
| 2012 | 1.9 Billion INR | 65.36% |
| 2011 | 1.15 Billion INR | 54.72% |
| 2010 | 743.87 Million INR | 30.14% |
| 2009 | 571.59 Million INR | 7.11% |
| 2008 | 533.65 Million INR | 18.53% |
| 2007 | 450.23 Million INR | 41.81% |
| 2006 | 317.49 Million INR | 24.28% |
| 2005 | 255.46 Million INR | 30.28% |
| 2004 | 196.08 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 6.29 Billion INR | 112.43% |
| 2024 Q1 | 2.96 Billion INR | 21.43% |
| 2023 Q4 | 2.44 Billion INR | -16.81% |
| 2023 Q1 | 2.48 Billion INR | 61.99% |
| 2023 Q2 | 2.78 Billion INR | 12.15% |
| 2023 FY | 10.36 Billion INR | 56.63% |
| 2023 Q3 | 2.93 Billion INR | 5.43% |
| 2022 Q4 | 1.53 Billion INR | -10.52% |
| 2022 FY | 6.61 Billion INR | -18.08% |
| 2022 Q2 | 2.03 Billion INR | 7.37% |
| 2022 Q3 | 1.71 Billion INR | -16.08% |
| 2022 Q1 | 1.89 Billion INR | 5.9% |
| 2021 FY | 8.07 Billion INR | -9.26% |
| 2021 Q4 | 1.79 Billion INR | -13.69% |
| 2021 Q1 | 1.89 Billion INR | -20.64% |
| 2021 Q3 | 2.07 Billion INR | -10.13% |
| 2021 Q2 | 2.31 Billion INR | 22.16% |
| 2020 Q3 | 2.12 Billion INR | -13.57% |
| 2020 Q4 | 2.38 Billion INR | 12.25% |
| 2020 FY | 8.9 Billion INR | 51.48% |
| 2020 Q1 | 1.95 Billion INR | 31.75% |
| 2020 Q2 | 2.45 Billion INR | 25.98% |
| 2019 Q3 | 1.62 Billion INR | 5.13% |
| 2019 Q2 | 1.54 Billion INR | 6.07% |
| 2019 Q1 | 1.45 Billion INR | 24.4% |
| 2019 FY | 5.87 Billion INR | 18.83% |
| 2019 Q4 | 1.48 Billion INR | -8.75% |
| 2018 FY | 4.94 Billion INR | -18.54% |
| 2018 Q4 | 1.17 Billion INR | 32.04% |
| 2018 Q3 | 886.4 Million INR | -40.4% |
| 2018 Q2 | 1.48 Billion INR | 5.99% |
| 2018 Q1 | 1.4 Billion INR | 14.18% |
| 2017 Q2 | 1.69 Billion INR | 48.35% |
| 2017 Q1 | 1.14 Billion INR | -19.96% |
| 2017 FY | 6.07 Billion INR | -9.02% |
| 2017 Q4 | 1.22 Billion INR | -32.67% |
| 2017 Q3 | 1.82 Billion INR | 7.89% |
| 2016 Q3 | 1.62 Billion INR | -3.78% |
| 2016 Q2 | 1.69 Billion INR | 10.09% |
| 2016 Q1 | 1.53 Billion INR | 17.83% |
| 2016 FY | 6.67 Billion INR | 23.0% |
| 2016 Q4 | 1.42 Billion INR | -12.42% |
| 2015 Q4 | 1.3 Billion INR | -14.31% |
| 2015 FY | 5.42 Billion INR | 19.61% |
| 2015 Q2 | 1.42 Billion INR | 27.27% |
| 2015 Q3 | 1.52 Billion INR | 6.46% |
| 2015 Q1 | 1.12 Billion INR | -6.39% |
| 2014 Q1 | 846.7 Million INR | 0.0% |
| 2014 Q4 | 1.19 Billion INR | -10.02% |
| 2014 FY | 4.53 Billion INR | 39.64% |
| 2014 Q3 | 1.33 Billion INR | 14.78% |
| 2014 Q2 | 1.16 Billion INR | 37.12% |
| 2013 FY | 3.24 Billion INR | 70.7% |
| 2012 Q1 | - INR | 0.0% |
| 2012 FY | 1.9 Billion INR | 65.36% |
| 2012 Q2 | - INR | 0.0% |
| 2012 Q3 | - INR | 0.0% |
| 2012 Q4 | - INR | 0.0% |
| 2011 FY | 1.15 Billion INR | 54.72% |
| 2010 FY | 743.87 Million INR | 30.14% |
| 2009 FY | 571.59 Million INR | 7.11% |
| 2008 FY | 533.65 Million INR | 18.53% |
| 2007 FY | 450.23 Million INR | 41.81% |
| 2006 FY | 317.49 Million INR | 24.28% |
| 2005 FY | 255.46 Million INR | 30.28% |
| 2004 FY | 196.08 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | -241.733% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 53.375% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | -119.143% |
| Granules India Limited | 6.81 Billion INR | -188.663% |
| Indoco Remedies Limited | 1.29 Billion INR | -1422.364% |
| Achyut Healthcare Limited | 4.43 Million INR | -443282.154% |
| Alkem Laboratories Limited | 19.46 Billion INR | -1.107% |
| Alpa Laboratories Limited | 184.49 Million INR | -10565.377% |
| Brooks Laboratories Limited | 14.44 Million INR | -136169.391% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | -1045.694% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -1498.48% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 70.947% |
| Eris Lifesciences Limited | 5.18 Billion INR | -279.745% |
| FDC Limited | 2.98 Billion INR | -558.939% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | -202.617% |
| Gufic Biosciences Limited | 1.32 Billion INR | -1379.596% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | -345.132% |
| Ipca Laboratories Limited | 7.98 Billion INR | -146.564% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -3772.493% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 13049.255% |
| Lasa Supergenerics Limited | -458 Million INR | 4396.307% |
| Laurus Labs Limited | 3.94 Billion INR | -398.336% |
| Lupin Limited | 28.04 Billion INR | 29.835% |
| Mankind Pharma Limited | 21.51 Billion INR | 8.554% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -19518.445% |
| Megasoft Limited | -121.1 Million INR | 16348.266% |
| NATCO Pharma Limited | 25.96 Billion INR | 24.207% |
| Piramal Pharma Limited | 4.55 Billion INR | -331.813% |
| RPG Life Sciences Limited | 2.29 Billion INR | -758.409% |
| Sigachi Industries Limited | 1.47 Billion INR | -1235.053% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 81.135% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | -327.058% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -7794.572% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -3353.879% |
| Windlas Biotech Limited | 1.29 Billion INR | -1414.932% |
| ZIM Laboratories Limited | 253.82 Million INR | -7652.187% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 54.352% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 578.18% |
| Divi's Laboratories Limited | 33.08 Billion INR | 40.516% |
| Hester Biosciences Limited | 364.81 Million INR | -5293.849% |
| Procter & Gamble Health Limited | 2.78 Billion INR | -606.292% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -4200.636% |
| Bal Pharma Limited | 233.9 Million INR | -8312.374% |
| Strides Pharma Science Limited | 5.22 Billion INR | -276.541% |
| Venus Remedies Limited | 534.65 Million INR | -3580.401% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | -529.046% |
| Nectar Lifesciences Limited | 923.8 Million INR | -2030.025% |
| Shilpa Medicare Limited | 1.36 Billion INR | -1340.218% |
| Aarti Drugs Limited | 7.14 Billion INR | -175.256% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | -1132.296% |
| Suven Life Sciences Limited | -1.22 Billion INR | 1705.233% |
| Ind-Swift Limited | 1.22 Billion INR | -1505.047% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | -37.769% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 610.714% |
| Themis Medicare Limited | 392.58 Million INR | -4912.188% |
| Hikal Limited | 32.11 Million INR | -61180.909% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 22.332% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | -3040.83% |
| Wockhardt Limited | -670 Million INR | 3036.91% |
| Jubilant Pharmova Limited | 5.18 Billion INR | -279.212% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -216880.383% |
| Neuland Laboratories Limited | 5.31 Billion INR | -270.007% |
| Morepen Laboratories Limited | 4.17 Billion INR | -371.445% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -9357.967% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -71563.268% |